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We are grateful to the editors of SPM for having invited
comments on our report and to the distinguished commenta-
tors for their thoughtful remarks. We appreciate the opportu-
nity that is given us here to respond.
The remarks of van den Brink, Davoli and Perucci, Verthein
et al. and Monteiro are mostly complimentary of, and lar-
gely complementary to, our report and, in that sense, do not
require extensive replies. The criticisms of Newman will be
dealt with in more detail.
Van den Brink’s comments are generally supportive of our
approach and conclusions, though he does regret certain 
absences in the paper. It is correct that stage of illness (as 
opposed to stage of treatment) and treatment objectives are
not explicitly included, as such. This is because we felt that
the modular approach in our scenarios allows the therapists
to implicitly consider illness severity and the therapeutic 
response to targeted problems.  
Van den Brink has correctly made the conceptual distinction
between cure and care. However, it is important to empha-
sise that in real life, even if cure is the eventual goal, care
(i.e., MMT) may be used for different reasons on the diffi-
cult pathway leading to abstinence.
Physical examination and blood tests are not listed in our list
of initial assessments, though they could very well have been.
The reason, as van den Brink understands, is because in our
system the first level of treatment is with the primary care phy-
sician and it is assumed that this assessment has been done if
the patient’s condition and physician’s need for information
requires. Physical examination and blood tests were thus con-
sidered to be part of usual care and left out of the framework
of the specific criteria examined. As can be seen from the ac-
tual ratings, all the elements we identified for initial assess-
ment were considered appropriate by the expert panel.
A further element that van den Brink misses is substitution
with other opioids. There are at least two reasons for this
1. more than 90% of maintenance/substitution is based on
methadone, and
2. the other substances are more generally used in case of
failure of methadone.
Concerning comparable figures of disagreement, we can
confirm that the figures for disagreement (and uncertainty)
are, in fact, rather low compared to previous experience
(ours and others) in applying the RAND method to health-
care interventions. For example, panels that some of us (IPV,
BB) have performed have shown disagreement figures of
6% for laminectomy(Vader et al. 2000), 14% for colonos-
copy (Burnand et al. 1998), 8% for gastroscopy(Vader et al.
1997).
Monteiro’s perspective from the World Health Organization
is enlightening and we have little to add to his remarks. We
can only echo his insistence that “research continues to be a
priority” in this field and his reminder that such research
must be at once well-designed, well-conducted and close to
the reality of every-day practice. We are also acutely aware,
as Monteiro reminds us, that the difficulties encountered in
changing clinical practice are a major obstacle to improving
the quality of care and that this will require a wide range of
incentives in various components and at all levels of our
health care systems.
The call for international collaboration is vital and is reflec-
ted in our own recommendation to the Swiss authorities that
they foster and intensify such collaboration. It is hoped that
the insights provided from this experience in one healthcare
system may indeed “serve as an incentive to donors, interna-
tional organisations and research institutions to mobilize 
resources needed to improve the care of people with heroin
dependence.”
Verthein et al. have underlined important areas where there
were higher levels of disagreement in the Swiss expert panel
and have linked that disagreement to the fact that these are
precisely areas that are begging for high-quality research.
Such areas include “psycho-social interventions”, “co-treat-
ment” and the major question of “treatment withdrawal”.
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Concerning regulation, we understand the sensitive nature of
regulation in an area that is highly charged emotionally and
the delicate balance required in providing regulation that is
as little as possible, but as much as necessary. The political
context here cannot be ignored and we do hope that the
bringing together of experts with differing perspectives, dif-
fering fields of expertise and differing approaches will act as
a catalyst for the wider arena to find consensus where feasible
and to initiate and fund the necessary research to answer the
questions where consensus is not yet possible.
As Verthein et al. point out, the Swiss context is exemplary in
some respects. We have enjoyed a relative (to other nations)
liberal attitude towards prescription and financing of MMT,
especially in the framework of combating the AIDS/HIV
epidemic. Among the encouraging results is “coverage” of
substitution among the opiate-dependent population which
is among the highest in the world, attaining about 2/3 of the
opiate-dependents.
Davoli and Perucci, from their unique perspective of the
Cochrane Collaboration, give us a healthy reminder of the
many questions which are not answered in our report and
most of which still beg for clear answers from research. They
underline the important point that the indication for MMT
must take place within a network of care and requires both
medical and social consensus.
Concerning the important distinction between evidence-ba-
sed recommendations and recommendations based on clini-
cal or subjective judgement, or, as in our case, from panel
judgement, we concur that this is important. For that reason,
we strongly recommend that the results from the panel be
read, as they were developed, i.e., in conjunction with the
Swiss and international literature reviews which are freely
available on the internet. We feel moved to add, however,
that an ideal world where every question in health care will
have a timely answer based on methodologically sound re-
search will probably never exist. We therefore need methods
to support or guide health care decisions that will, of neces-
sity, be based on lower quality evidence.
The commentary from Newman is the only one that is
clearly critical of the report. For this reason, we will allow
ourselves to dwell in more detail on his remarks. Admittedly,
he had difficulties understanding the objectives and the 
method and we feel that several of his remarks are due to
misunderstandings.
Newman’s finds incomprehensible our use of the concept of
“post-cure phase of treatment”. We assumed it was obvious
that we were not using “cure” in the sense he implies (“ad-
diction is incurable”), but rather in the alternative meaning
as “a course or period of treatment”. In that sense, the “post-
cure” phase of care would be that period following the with-
drawal of methadone maintenance treatment, if and when
the patient and/or therapist decides that it should be with-
drawn. This phase obviously requires special attention.
Newman also takes issue with our recommendation that na-
tionally accepted practice guidelines be developed, “dissemi-
nated, promoted and used, and rigorously evaluated for
compliance and outcome.” He questions the necessity of
such a process, given the existence of national guidelines in
17 countries.
There are many reasons why the process is necessary. Some
of the problems with current guidelines are identified in the
commentaries by van den Brink, Monteiro, Davoli and 
Perucci. Simply because 17 countries (including Switzer-
land) have previously developed practice guidelines for 
methadone maintenance treatment is by no means a guaran-
tee that those guidelines are up-to-date, scientifically sound,
concordant in their detailed recommendations, relevant to
the Swiss context, complete in their coverage of the impor-
tant questions or acceptable to those who are called upon to
use them. The science of guidelines development and evalua-
tion is really in its infancy and, given the on-going evolution
of knowledge, there will always be a need to renew, update
or adapt guidelines.
As to the need for “rigorous evaluation” of compliance and
outcome, Newman seems to have misunderstood this to
mean “rigorous enforcement” of compliance. That is not
what we wrote, nor what we intended. We hope that, with so
many open questions in this vital field of health care, New-
man will have no trouble understanding our call for “rigo-
rous evaluation” of both compliance and outcome. As the
international and national literature reviews (referenced in
our paper and freely available on the web) indicated, this
field is plagued with an over-abundance of poor quality stu-
dies and a paucity of high-quality research. No evaluation of
the “outcome” of guidelines implementation has any sense if
there is not a simultaneous – and rigorous – evaluation of
the “compliance” with those guidelines. Otherwise, there is
no possible way to establish the link between the desired 
outcome (or its absence) and the guidelines themselves. For
example, one set of patients may fair poorly because the 
guidelines were simply bad (and should be discarded) or 
because the guidelines were good but were not followed. The
rigorous evaluation required to answer that fundamental
question has been absent in so much work on the quality 
of practice guidelines in healthcare.
Newman finds that the conclusions of the report range from
the self-evident to the incomprehensible, and he questions
the qualifications of the experts identified for the panel.
What may be self-evident to a highly accomplished interna-
tional expert like Newman, may not be for the primary care
S27Kommentare | Commentaries
Soz.- Präventivmed. 48 Supple 1 (2003) S25–S27
© Birkhäuser Verlag, Basel, 2003
Vader JP, et al.
Authors reply to commentators
References
Burnand B, Vader JP, Froehlich F, et al. (1998).
Reliability of panel based guidelines for colonos-
copy: an international comparison. Gastrointest
Endosc 47: 162–6.
Vader JP, Burnand B, Froehlich F, et al. (1997).
Appropriateness of upper gastrointestinal 
endoscopy: comparison of American and Swiss
criteria. Int J Qual Health Care 9: 87–92.
Vader JP, Porchet F, Larequi-Lauber T, Dubois
RW, Burnand B (2000). Appropriateness of sur-
gery for sciatica: reliability of guidelines from
expert panels. Spine 25: 1831–6.
physician in the field who will be prescribing methadone and
caring for the dependent patient. 
A word about the Swiss context may also help clear up 
misunderstandings. We deliberately chose a panel of Swiss
experts, from a variety of backgrounds, rather than a panel
of internationally renowned academics, because we were
concerned about the acceptance of guidelines in the Swiss
context. In Switzerland, methadone prescription is not 
reserved for specialists, nor decided in closed scientific
circles.  Rather, it is undertaken in therapeutic networks with
the primary care physician at the centre. This requires con-
sensus and cooperation, on the front lines, with social wor-
kers, pharmacists, psychologists and others. Without such
collaboration and consensus, treatment is foredoomed to 
failure. It is because of this approach that the coverage of
substitution treatment has attained a relatively high level in
our country. It is also because of that context that the 
“experts” we identified were not a group of ivory-tower aca-
demics – though some are accomplished academics –, but a 
representative group of respected therapists, responsible 
for the prescription of methadone in a multidisciplinary 
network.
This is also in keeping with the RAND panel approach
which seeks to combine scientific evidence (found in the lite-
rature review) with clinical expertise (present in our panel).
We hope the above explanations will assist Newman, and
others who may have similar misgivings, to better under-
stand the work that was done and the reasons for the ap-
proach taken. We thank Newman for his remarks which 
allowed us to address these points.
